Mutations of Helicobacter pylori Associated with Fluoroquinolone Resistance in Korea

Helicobacter

Volumn 16, Issue 4, 2011, Pages 301-310

  Lee, Jung W ^a,b   Kim, Nayoung ^a,b   Nam, Ryoung H ^a   Park, Ji H ^b   Kim, Jung M ^c   Jung, Hyun C ^b   Song, In S ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

Eradication; Helicobacter pylori; Moxifloxacin; Resistance; Second line

Indexed keywords

MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; DNA SEQUENCE; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL;

AGED; ANTI-BACTERIAL AGENTS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KOREA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

HELICOBACTER PYLORI;

EID: 79960470467     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2011.00840.x     Document Type: Article

References (40)

1. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597-604.
2. Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010;15(Suppl 1):1-6.
3. Kim N, Park RY, Cho SI, et al. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol 2008;42:448-54.
4. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
5. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007;133:659-72.
6. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
7. Vakil N. H. pylori treatment: new wine in old bottles? Am J Gastroenterol 2009;104:26-30.
8. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
9. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006;6:699-709.
10. Kim N, Kim JJ, Choe YH, et al. [Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea]. Korean J Gastroenterol 2009;54:269-78.
11. Kim JM, Kim JS, Jung HC, Kim N, Song IS. [Antibiotic resistance of Helicobacter pylori isolated from Korean patients in 2003]. Korean J Gastroenterol 2004;44:126-35.
12. Kim N, Park SH, Seo GS, et al. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. Helicobacter 2008;13:542-9.
13. Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010;15:38-45.
14. Mantzaris GJ, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol 2002;14:1237-43.
15. Cheon JH, Kim N, Lee DH, et al. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006;11:46-51.
16. O'Connor A, Gisbert J, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2009;14(Suppl 1):46-51.
17. Antos D, Schneider-Brachert W, Bastlein E, et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006;11:39-45.
18. Nishizawa T, Suzuki H, Nakagawa I, et al. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication. J Gastroenterol Hepatol 2008;23(Suppl 2):S167-70.
19. Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005;56:965-7.
20. Yoon H, Kim N, Lee BH, et al. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 2009;14:77-85.
21. Reece RJ, Maxwell A. DNA gyrase: structure and function. Crit Rev Biochem Mol Biol 1991;26:335-75.
22. Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997;388:539-47.
23. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995;39:107-11.
24. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational (Suppl.) M100-S17. Wayne, PA: CLSI, 2007.
25. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003;47:3942-4.
26. Miyachi H, Miki I, Aoyama N, et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 2006;11:243-9.
27. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;5:321-31.
28. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.
29. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
30. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 2009;7:145-8.
31. Sharara AI, Chaar HF, Racoubian E, et al. Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection. Helicobacter 2004;9:255-61.
32. Suzuki H, Nishizawa T, Muraoka H, Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother 2009;53:1720-1.
33. Hwang TJ, Kim N, Kim HB, et al. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol 2010;44:536-43.
34. Chen FJ, Lo HJ. Molecular mechanisms of fluoroquinolone resistance. J Microbiol Immunol Infect 2003;36:1-9.
35. Han SR, Bhakdi S, Maeurer MJ, Schneider T, Gehring S. Stable and unstable amoxicillin resistance in Helicobacter pylori: should antibiotic resistance testing be performed prior to eradication therapy? J Clin Microbiol 1999;37:2740-1.
36. Liu ZQ, Zheng PY, Yang PC. Efflux pump gene hefA of Helicobacter pylori plays an important role in multidrug resistance. World J Gastroenterol 2008;14:5217-22.
37. Kim JM, Kim JS, Kim N, et al. Gene mutations of 23S rRNA associated with clarithromycin resistance in Helicobacter pylori strains isolated from Korean patients. J Microbiol Biotechnol 2008;18:1584-9.
38. Hung KH, Sheu BS, Chang WL, et al. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a university hospital in Southern Taiwan. Helicobacter 2009;14:61-5.
39. Cambau E, Allerheiligen V, Coulon C, et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 2009;47:3600-7.
40. Kawai T, Yamagishi T, Yagi K, et al. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol 2008;23(Suppl 2):S171-4.